Cargando…
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
BACKGROUND: HVTN 505 was a human immunodeficiency virus type 1 (HIV-1) preventive vaccine efficacy trial of a DNA/recombinant adenovirus serotype 5 (rAd5) vaccine regimen. We assessed antibody responses measured 1 month after final vaccination (month 7) as correlates of HIV-1 acquisition risk. METHO...
Autores principales: | Fong, Youyi, Shen, Xiaoying, Ashley, Vicki C, Deal, Aaron, Seaton, Kelly E, Yu, Chenchen, Grant, Shannon P, Ferrari, Guido, deCamp, Allan C, Bailer, Robert T, Koup, Richard A, Montefiori, David, Haynes, Barton F, Sarzotti-Kelsoe, Marcella, Graham, Barney S, Carpp, Lindsay N, Hammer, Scott M, Sobieszczyk, Magda, Karuna, Shelly, Swann, Edith, DeJesus, Edwin, Mulligan, Mark, Frank, Ian, Buchbinder, Susan, Novak, Richard M, McElrath, M Juliana, Kalams, Spyros, Keefer, Michael, Frahm, Nicole A, Janes, Holly E, Gilbert, Peter B, Tomaras, Georgia D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018910/ https://www.ncbi.nlm.nih.gov/pubmed/29325070 http://dx.doi.org/10.1093/infdis/jiy008 |
Ejemplares similares
-
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
por: deCamp, Allan C., et al.
Publicado: (2017) -
P15-15. Advocates' perspectives on community engagement in the HVTN 505
por: Warren, M, et al.
Publicado: (2009) -
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019) -
Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010) -
A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)